Compare Merck & Co., Inc. (MRK) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Invesco Preferred ETF — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Invesco Preferred ETF trades at $10.79. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Invesco Preferred ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| MRK | PGX | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | — |
52-Week High | $129.52 | $11.87 |
52-Week Low | $77.60 | $10.81 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
PGX trades at $10.79, down 0.64% on the day, with a bearish technical outlook from moving averages. The ETF shows neutral momentum oscillators. Recent corporate actions include scheduled dividends for mid-2026. News highlights institutional selling and concerns over the fund's risk-return profile in the preferred stock space.
The outlook remains cautious due to structural subordination risks and interest rate sensitivity. Analyst sentiment is negative, citing capped upside and full participation in downturns. Key risks include credit defaults and macroeconomic shifts affecting preferred securities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
